Daniel De Boer biography
Daniel Anton De Boer serves as Chairman of the Management Board, Chief Executive Officer of the Company. Daniel de Boer is our founding Chief Executive Officer since our incorporation in 2012. Daniel is a serial-entrepreneur and passionate advocate for rare disease patients. He assembled a group of successful biotech executives as co-founders and built a team of a 150 experienced scientists and drug developers, devoted to creating RNA therapies for patients in need. Under Daniel’s leadership ProQR initiated clinical trials in multiple development programs for rare diseases, and raised over € 300M in funding, including an IPO on Nasdaq. Daniel is responsible for the overall strategy and general business in the company. Before founding ProQR, Daniel was founder and Chief Executive Officer of RNA Systems, PC Basic and Running IT, companies he led through phases of growth, developing and launching several products in multiple European countries. Daniel was also a co-founder of Amylon Therapeutics, a company developing therapies for genetic brain diseases. In 2018 Daniel was named "Emerging Entrepreneur of the Year" by EY. In 2019 Daniel was selected for the Young Global Leaders program at the World Economic forum.
What is the salary of Daniel Boer?
As the Chairman of the Management Board and Chief Executive Officer of ProQR Therapeutics N.V, the total compensation of Daniel Boer at ProQR Therapeutics N.V is $2,265,000. There are no executives at ProQR Therapeutics N.V getting paid more.
